

RESEARCH ARTICLE

Molecular features of steroid-binding antidins and their use for assaying serum progesterone

Nitin Agrawal¹, Soili I. Lehtonen², Meri Uusi-Mäkelä², Purvi Jain², Sari Viitala³, Juha A. E. Määttä², Niklas Kähkönen², Latifeh Azizi², Tiina A. Riihimäki², Markku S. Kulomaa², Mark S. Johnson¹, Vesa P. Hytönen^{2,4*}, Tomi T. Airene^{1*}

1 Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland, **2** BioMediTech Institute and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, **3** University of Eastern Finland, School of Pharmacy, Kuopio, Finland, **4** Fimlab Laboratories, Tampere, Finland

☯ These authors contributed equally to this work.

* tomii.airene@abo.fi (TTA); vesa.hytonen@tuni.fi (VPH)



OPEN ACCESS

Citation: Agrawal N, Lehtonen SI, Uusi-Mäkelä M, Jain P, Viitala S, Määttä JAE, et al. (2019) Molecular features of steroid-binding antidins and their use for assaying serum progesterone. PLoS ONE 14(2): e0212339. <https://doi.org/10.1371/journal.pone.0212339>

Editor: Atsuko Yamashita, Okayama Daigaku, JAPAN

Received: August 20, 2018

Accepted: January 31, 2019

Published: February 20, 2019

Copyright: © 2019 Agrawal et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by grant funding from the Academy of Finland (257814 (M.S.J.), 272283 (M.S.J.), 263540 (V.P.H.), 290506 (V.P.H.), 261285 (M.S.K.), and 272288 (M.S.K.)); Sigrid Juselius Foundation; Joe, Pentti and Tor Borg Memorial Fund; Orion Research Foundation sr; Academy of Finland FIRI program (141398); and Åbo Akademi Center of Excellence in Cell

Abstract

Chicken avidin (Avd) and streptavidin from *Streptomyces avidinii* are extensively used in bionanotechnology due to their extremely tight binding to biotin ($K_d \sim 10^{-15}$ M for chicken Avd). We previously reported engineered Avds known as antidins, which have micro- to nanomolar affinities for steroids, non-natural ligands of Avd. Here, we report the 2.8 Å X-ray structure of the sbAvd-2 (I117Y) antidin co-crystallized with progesterone. We describe the creation of new synthetic phage display libraries and report the experimental as well as computational binding analysis of progesterone-binding antidins. We introduce a next-generation antidin with 5 nM binding affinity for progesterone, and demonstrate the use of antidins for measuring progesterone in serum samples. Our data give insights on how to engineer and alter the binding preferences of Avds and to develop better molecular tools for modern bionanotechnological applications.

Introduction

Due to the highly stable beta-barrel structure, high resistance to a wide range of temperature and pH changes, rather small size (around 60 kDa for a tetramer) and, especially, the extraordinary tight binding to a small molecule D-biotin, avidins (Avds) are exploited in a number of practical life science applications and biotechnological assays. These include techniques for imaging, purification, labeling, targeting and detection [1,2]. The structure-function relationship of the Avd-biotin complex is well known, especially for the classical tetrameric chicken Avd and streptavidin from *Streptomyces avidinii*, and has been widely explored e.g. through rational mutagenesis [3]. Several Avds with altered biological and physiochemical properties have been developed and produced [1,3–5], including e.g. Avds with higher thermal stability [4,6]; single-chain and dual-chain Avds—circularly permuted Avds consisting of four or two monomers, respectively, fused into a single polypeptide chain—that have potential to bind

Stress and Aging. Fimlab Laboratories (Tampere, Finland) provided support in the form of salaries for author VPH and research materials for the group led by VPH. Fimlab and the other funders had no influence in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests: The authors declare that no competing interests exist. VPH is affiliated to Fimlab laboratories, which has supported VPH financially, and provided research material support to the group led by VPH.

simultaneously up to four different ligands as well as monomeric avidins, enabling applications where oligomeric assembly is disadvantageous [5,7–11]. Despite intensive research focusing on Avd structure and function, the biological role of Avd remains partially unclear. In chicken, Avd expression is induced by injury and inflammation [12] and Avd appears to be beneficial for the developing embryo in birds [13]. Numerous microbial genomes also carry an Avd gene, which may offer a tool for bacteria *e.g.* to compete against organisms incapable of biotin synthesis, such as nematodes in soil [14], and we can speculate on potential metabolic advantages to plants like soy bean having a symbiotic relationship with *Bradyrhizobium diazoefficiens*—a bacteria having the gene.

Currently, the number of stable and high-affinity small molecule-binding protein-based scaffolds for biotechnological use is still limited [15–17]. While several scaffolds appear suitable for binding of peptide/protein ligands, *e.g.* anticalins tailored from lipocalins of the calycin protein superfamily to bind small hapten-like compounds and large protein antigens [18], scaffolds suitable for tight binding of small molecules are rare. The Avd scaffold provides an optimal—in terms of both stability and physicochemical properties—ligand-binding site for small molecules; the binding site is lined with several polar residues available for hydrogen-bonding (H-bonding) and aromatic and hydrophobic residues for providing stability through van der Waals contacts and hydrophobic interactions [19]. Since the discovery of the extremely tight Avd-biotin interaction [20,21], the search for ligands other than biotin that could also bind Avds has been going on and has resulted in the identification of ligands, such as HABA (2-(4'-hydroxybenzene)azobenzoic acid) and its derivatives—a group of azo compounds binding to Avd [22] and streptavidin [23] with a micromolar affinity ($K_d \approx 6 \times 10^{-6}$ M for Avd-HABA complex). In addition, several bacterial Avds, such as streptavidin [24], bradavidin [25] and hoefavidin [26], have intrinsic peptide ligands formed from their extended C-terminal regions that bind to their ligand-binding sites in the absence of biotin, typically only with moderate (micromolar) affinity. Peptide ligands have also been engineered and include tags like Avi- and AviD-tag [27,28], Strep-tag [29], Strep-tag II [29–33], different Nano-tags [34,35] and SBP-tag [36] with affinities on the micromolar (Avi-, AviD-, Strep-tag I and II) to nanomolar (Nano-tags) scale.

The binding site of Avds has been engineered by both mutating single residues involved directly in biotin binding and by manipulating the loop regions of Avds important for ligand recognition and specificity [37,38]. The L3,4-loop in particular, with a vital role for biotin binding, has been an active target for mutagenesis [5,7–10]. In our recent study, we reported antidins, *i.e.* engineered Avds recognizing the non-native ligands progesterone, testosterone, hydrocortisone, cholic acid and ketoprofen. Those antidins were created by engineering the L1,2-loop together with the L3,4-loop or L5,6-loop regions using a directed evolution method for mutagenesis and the phage display technique for selection [38]. In comparison to natural Avd, antidins showed reduced binding affinity for biotin and had increased affinity towards progesterone, as analyzed *in vitro* using calorimetry, fluorometry and microplate assays, and hence antidins have potential to be used as novel diagnostic reagents [38].

Here, we co-crystallized the sbAvd-2 (I117Y) antidin together with progesterone [PDB:5LUR]—the sbAvd-2 (I117Y) mutant has modified L1,2 and L3,4 loop regions and includes the stabilizing mutation I117Y [22] not present in chicken Avd. We created new synthetic phage display libraries and report the fluorometry-based progesterone-binding analysis of new enriched antidins, and of recently reported ones. We focus in more detail on one of our most potent new antidins, sbAvd-7, and demonstrate its potential use for assaying the concentration of progesterone in serum samples. Moreover, homology modelling and docking analysis was conducted to enhance our understanding of the experimental observations at atomic resolution. Our data help us to better understand the binding mode of progesterone with

antidiins and may help in developing improved forms of antidiins for biotechnological applications, including for diagnostics.

Results

Overall structure of sbAvd-2 (I117Y)—Progesterone complex

The sbAvd-2 antidiin was previously shown to bind progesterone with 111 nM affinity. The I117Y mutation, originating from avidin-related protein 4 (AVR4) [39] and known to stabilize the 1,3 interface of tetrameric Avds, slightly decreased the affinity (180 nM) for progesterone while improving the thermal stability. Here, the X-ray structure of sbAvd-2 (I117Y) in a putative complex with progesterone [PDB:5LUR] was determined at 2.80 Å resolution (see Table 1 for structure determination statistics; Fig 1). This antidiin was co-crystallized with progesterone and the two binding sites of the asymmetric unit have clear blobs of electron density, most likely representing progesterone molecules even though the density at the binding sites was worse, or less interpretable, than for most regions of the polypeptide chains (Fig 2). The biological unit was clearly tetrameric despite there being only two monomers in the asymmetric unit; subunits I-IV were numbered according to [19]. Similarly to our recently published apo structure of sbAvd-2 (I117Y) [PDB:4U46], the overall fold of the complex structure closely resembled that of chicken Avd [19]. Residues Asn38-Ser41 within the L3,4 loop were missing from the final structure; they could not be built because of the lack of interpretable electron density for these residues (Fig 3).

Progesterone-binding mode of sbAvd-2 (I117Y) mutant. Unlike the biotin ligand in the chicken Avd-biotin complex [PDB:2AVI], which is stabilized by eleven hydrogen bonds and

Table 1. Structure determination statistics for [PDB:5LUR].

DATA PROCESSING ^a	
Space group	P2 ₁ 2 ₁ 2
Unit cell:	
a, b, c, (Å)	74.48, 79.80, 43.07
α, β, γ (°)	90, 90, 90
Wavelength (Å)	0.967700
Beamline	ID30A-3, ESRF
Resolution (Å) ^b	25–2.80 (3.0–2.80)
Observed Reflections ^b	28590 (4922)
Unique Reflections ^b	7466(1249)
I/σ ^b	10.36 (3.22)
R _{factor} (%) ^b	12.0 (41.7)
Completeness ^b	96.1 (98.5)
REFINEMENT	
Matthews coefficient	2.10
R _{work} (%) ^c	17.6%
R _{free} (%) ^c	23.9%
Monomers (asymmetric unit)	2
R.m.s.d:	
Bond lengths (Å)	0.0125
Bond angles (°)	1.71

^aThe numbers in parenthesis refer to the highest resolution bin

^bData from XDS [40]

^cData from Refmac 5 [41]

<https://doi.org/10.1371/journal.pone.0212339.t001>




Fig 1. Overall structure of the sbAvd-2 (I117Y)-progesterone complex [PDB:5LUR]. Subunits I (orange), II (brown), III (magenta) and IV (blue) of the biological unit are numbered according to [19]. The position of residues Arg13-Met14-Asn15-His16 (13-16); Tyr33 (33); Ala35-Thr36-Val37-Asn38 (arrow head); Thr77 (T); and Tyr117 (Y; stick model) are indicated with black color in the cartoon models of the subunits I-IV. The progesterone ligands are drawn as spheres; only the oxygen atoms (red) of the 20-acetyl group (D-ring) of subunits III and IV are clearly seen. The N-termini (N; * for subunits II and III) and C-termini (C) are indicated. The positions of the residues in the L3,4 and L6,7 loop that could not be built into the final structure due to uninterpretable electron density map are indicated by dashed lines.

<https://doi.org/10.1371/journal.pone.0212339.g001>

several hydrophobic/van der Waals interactions [19], in our new sbAvd-2 (I117Y)-progesterone complex structure the ligand has only a few residues within 4 Å to stabilize its binding (Fig 4). Firstly, only two H-bonds are formed between sbAvd-2 (I117Y) and progesterone: the Asn118 Nδ (2.4 Å) and Trp97 Ne (3.0 Å) atoms form H-bonds with the 20-acetyl group (D-ring) of the ligand; by comparison, in chicken Avd [PDB: 2AVI] only Asn118 Oδ (2.8 Å) is H-bonded to the ureido ring of biotin while Trp97 Ne (3.9 Å) remains unbound. The oxygen atom of the ketone group at the other end of the progesterone (A-ring) is not forming H-bonds with the surrounding residues. Secondly, the Cδ and Cζ atoms of Phe79 are within a van der Waals and/or hydrophobic interaction distance (3.7 Å and 3.5 Å, respectively) of the 20-acetyl group of the ligand; and Met14, His16, Tyr33, Ala35, Val37, Trp70, Phe72, Thr77 and Trp110 (from the neighboring subunit) stabilize the binding of progesterone through van der Waals and hydrophobic interactions. All-in-all, the fit of progesterone to sbAvd-2 (I117Y) in the complex is much less optimal than biotin in the Avd-biotin structure; and progesterone does not stabilize the L3,4-loop (see below), in agreement with the lower binding free energy of steroids to sbAvids in comparison to the binding of biotin to Avd.

L1,2 and L3,4 loop. Dissimilar to the apo structure of sbAvd-2 (I117Y) [PDB:4U46] published previously [38], the L1,2 loop of the sbAvd-2 (I117Y)-progesterone structure is clearly stabilized in one major conformation, very likely needed to accommodate ligand binding: in the antidin-progesterone complex, Met14 and His16 of the L1,2 loop have clearly moved (in




Fig 2. Progesterone interaction with the key residues Met14, His16 and Asn118 of the sbAvd-2 (I117Y)-progesterone complex [PDB:5LUR]. The weighted 2Fo-Fc electron density map (blue mesh; contour level of 1.0σ) and an omit map (green mesh; contour level of 1.0σ) calculated in the absence of progesterone are shown. Carbon atoms are colored orange, nitrogen atoms blue, sulfur atom yellow and oxygen atoms red.

<https://doi.org/10.1371/journal.pone.0212339.g002>

comparison to the apo structure) towards the ligand and are within hydrophobic/van der Waals interaction distance of the ligand (Fig 3). However, the L3,4 loop of the progesterone complex structure is in the open conformation similar to the apo structure of sbAvd-2 (I117Y) [PDB:4U46]. This suggests that further sequence optimization of the L3,4 loop could result in the closed conformation of the loop and improve the affinity between progesterone and the antitoxin.

The I117Y mutation. We reported recently [38] that the I117Y point mutation improves the thermostability of sbAvd antitoxins similarly to what was originally shown for chicken Avd




Fig 3. Superimposition of the C α traces of subunit I of the sbAvd-2 (I117Y)-progesterone complex (green carbon atoms) [PDB:5LUR] and the apo structure of sbAvd-2 (I117Y) (magenta carbon atoms) [PDB:4U46]. Progesterone [PDB:5LUR] and the side chains of Met14 and His16 [PDB:5LUR, 4U46] are shown as sticks. The L1,2 and L3,4 loop regions are labeled. Black arrows indicate the L3,4 loop regions missing (uninterpretable electron density) from both of the structures. Nitrogen atoms are colored blue, oxygen atoms red and sulfur atoms yellow.

<https://doi.org/10.1371/journal.pone.0212339.g003>

[22]. This form was found to crystallize in the presence of progesterone and was thus selected for structural analysis. The I117Y mutation slightly reduced the affinity of progesterone to sbAvd-2 and it is possible that the Tyr117 residue in the mutant, located at the 1,3 subunit interface, affects the binding of progesterone indirectly by altering the conformation/spatial location of the adjacent Asn118.

Improved phagemid vector for phage display

To search for better binding antidins, we used phage display with an improved phagemid vector. The previously constructed and used Gateway cloning compatible phagemid vector, pGWphagemid [42], is based on the *ccdB* suicide gene that is not optimal when combined with F-episome bearing bacteria essential for phage display; F-episome bearing bacteria such as XL1-Blue are capable of producing the *ccdA* antidote, which prevents selection with *ccdB* to some extent [43], potentially leading to non-expressing bacterial clones and decreased screening efficacy. Therefore, we replaced the suicide gene *ccdB* with the *SacBR* gene, which has previously been used in plant cells immune to the *ccdB* toxin [44]. The resulting pGWSacBRphagemid vector was then successfully used for efficient screening of novel antidins using phage display (S1 Fig).




Fig 4. Comparison of the ligand-binding site of the sbAvd-2 (I117Y)-progesterone complex structure (green; subunit I) [PDB:5LUR] and the apo structure of sbAvd-2 (I117Y) (magenta) [PDB:4U46]. Residues within 4 Å around the ligand (thick sticks) in the sbAvd-2 (I117Y)-progesterone complex structure, and the equivalent residues in the apo structure are shown as sticks; the α traces of the subunits were superimposed. The side chain carbon atoms of Trp110 from the neighboring subunit of the complex structure are colored dark grey and, of the apo structure, light grey. Nitrogen atoms are colored blue, oxygen atoms red and sulfur atoms yellow. The H-bonds between progesterone and side chains of Trp97 and Asn118 of the complex structure are indicated by black dashed lines (distances in Ångströms).

<https://doi.org/10.1371/journal.pone.0212339.g004>

Novel Avd phage display libraries

Two novel DNA libraries, AvLib-4 and AvLib-5, were created to screen for novel binders for progesterone and hydrocortisone, respectively, based on the previously enriched antidin sequences [38]. The constructed Avd phage display libraries were based on the monovalent

display mode (3+3) and, due to the amber stop codon placed in between the Avd variants and the C-terminal pIII, the Avd variants could be expressed as tetramers on the surface of phages as described in [42]. The use of TRIM (trinucleotide mutagenesis) technology within the chemical synthesis process enabled preparation of DNA libraries with maximal diversity and good sequence coverage with a reasonable library size. After three rounds of selection with an automated magnetic particle processor, four antidins–sbAvd-7–10 –having mutations in the L1,2-loop and L3,4-loop regions (and at position 77; in comparison to chicken Avd) were selected from the progesterone panning AvLib-4 library, and six antidins–hbAvd-4–9 –having mutations in the L1,2-loop and L5,6-loop (and at positions 33, 40 and 118) were selected from the hydrocortisone panning AvLib-5 library (Table 2). Panning for hydrocortisone was also carried out using a 1:1 mixture of the AvLib-4 and AvLib-5 libraries but the hydrocortisone binders were dominantly enriched from the AvLib-5 library.

In comparison to our previous study [38], progesterone-binding antidins were here selected from AvLib-4 library by using free progesterone for the elution in the first panning round followed by elution by acid in the subsequent rounds. The idea was to favor the selection of target-specific binders over non-specific binders during the initial selection from the library, after which the binders should already show desired target specificity [45]. Non-specific elution was used on the 2nd and 3rd panning rounds, followed by small-scale amplification of the phages [38]. The enriched antidins showed significantly improved affinities for progesterone and, for the first time, an antidin (sbAvd-7) with $K_d < 10$ nM for progesterone was enriched.

Different phage elution strategies (acid, base, competing ligand and trypsin elution) were tested for hydrocortisone selection to achieve high-affinity clones—the most unique sequences were obtained by using free hydrocortisone. However, none of the new binders showed a significantly higher affinity for hydrocortisone in comparison to the binders reported earlier by [38] (the affinities were in the micromolar range) but instead they showed improved affinity for progesterone (see below). It might be that the conjugated hydrocortisone molecule used in the selection process was either too large to fit properly into the ligand-binding site of the mutated Avds or, alternatively, the conjugation site in hydrocortisone was not optimal and affected ligand binding. Nonetheless, these results demonstrate that it is possible to select progesterone binders not only from Avd phage display libraries specifically having the “RMNH” sequence replacement in the L1,2-loop but also from other libraries. Since the affinity for hydrocortisone was not improved in the antidins enriched from the AvLib-5 in comparison to our earlier study [38], we will focus here on the analysis of novel progesterone-binding antidins.

Progesterone-binding analysis of selected antidins

In our earlier study [38], the sbAvd-1–6 antidins, as well as the sbAvd-2 (I117Y) mutant, were experimentally tested for biotin, progesterone and testosterone binding using non-conjugated ligands in a fluorometry-based assay [38]; sbAvd-2 ($K_d = 111$ nM), sbAvd-5 (108 nM) and sbAvd-6 (117 nM) were observed as the tightest progesterone binders. These sbAvds differ from each other only at sequence positions 35–38 and, based on the structures of sbAvd-2 (I117Y) and sbAvd-6 (I117Y) complexed with progesterone, position 35 seems to be the most important for binding.

Of these new antidins, sbAvd-7–9, enriched for binding progesterone from the AvLib-4 library, and hbAvd-4, enriched for binding hydrocortisone from the AvLib-5, were found to be the tightest progesterone binders analyzed so far. Based on a fluorometric analysis measuring intrinsic fluorescence, the affinities for progesterone were within the low nanomolar range: hbAvd-4, $K_d = 39$ nM; sbAvd-8, 11 nM; sbAvd-9, 13 nM; and sbAvd-7, 5 nM.

Similarly to sbAvd-1–6 and sbAvd-2 (I117Y) [38], sbAvd-7–9 all have modified L1,2-loop residues 13–16 (RMNH) in comparison to chicken Avd (DLGS), supporting the idea of the

Table 2. Characteristics of AvLib library design and enriched sequences selected from the libraries based on ligand panning.

Library	L1,2 loop					L3,4 loop						L5,6 loop				I117Y	N118	Template gene	Library size (theoretical / actual ^a)	INPUT
	N12	D13	L14	G15	S16	Y33	T35	A36	V37	T38	T40	F72	S73	S75	T77					
AvLib-3 [34]	-	R	M	N	H	-	NNY degenerate codon				-	-	-	-	-	-	-	sbAvd-1	0.05 x 10 ⁶ /	
							enables 15/20 amino acids (excluding W, Q, E, M, K)												1.40 x 10 ⁶	
AvLib-4 ^b	-	R	M	N	H	all	T	A	V	Y	-	-	-	-	all	-	all	sbAvd-1	2.74 x 10 ⁶ /	
						except	Y	T	D	N					except		except		1.11 x 10 ⁹	
						C	P	Y	L	P					C		C			
							A	S	S	S										
								P	H											
AvLib-5 ^c	N	D			S	all					all	A	T	A			all		0.66 x 10 ⁶ /	
	Y	S	-	-	A	except	-	-	-	-	except	Y	A	Y	-	-	except	wtAvd	3.33 x 10 ⁶	
						C					C		Y				C			
Mutant	N12	D13	L14	G15	S16	Y33	T35	A36	V37	T38	T40	F72	S73	S75	T77	-	N118	From library	Target molecule	OUTPUT
hbAvd-4	-	-	-	-	A	F	-	-	-	-	P	A	Y	Y	-	-	A	AvLib-5	hydrocortisone	
hbAvd-5	-	S	-	-	A	H	-	-	-	-	D	A	Y	A	-	-	S	AvLib-5	hydrocortisone	
hbAvd-6	-	-	-	-	A	L	-	-	-	-	F	Y	Y	Y	-	-	G	AvLib-5	hydrocortisone	
hbAvd-7	-	-	-	-	A	I	-	-	-	-	W	A	Y	Y	-	-	A	AvLib-5	hydrocortisone	
hbAvd-8	-	-	-	-	A	-	-	-	-	-	N	A	Y	Y	-	-	L	AvLib-5	hydrocortisone	
hbAvd-9	-	S	-	-	A	A	-	-	-	-	K	Y	A	Y	-	-	A	AvLib-5	hydrocortisone	
sbAvd-7	-	R	M	N	H	-	A	S	L	N	-	-	-	-	A	-	-	AvLib-4	progesterone	
sbAvd-8	-	R	M	N	H	F	-	Y	S	Y	-	-	-	-	A	-	-	AvLib-4	progesterone	
sbAvd-9	-	R	M	N	H	-	Y	Y	L	P	-	-	-	-	A	-	-	AvLib-4	progesterone	
sbAvd-10	-	R	M	N	H	F	Y	A	D	P	-	-	-	-	G	-	-	AvLib-4	progesterone	
sbAvd-1 [38]	-	R	M	N	H	-	-	-	-	-	-	-	-	-	-	-	-	AvLib-3	progesterone	Previously
sbAvd-2 [38]	-	R	M	N	H	-	A	T	V	N	-	-	-	-	-	-	-	AvLib-3	progesterone	Characteri-
sbAvd-2 (I117Y) [38]	-	R	M	N	H	-	A	T	V	N	-	-	-	-	-	Y	-			zed antidiins
sbAvd-3 [38]	-	R	M	N	H	-	P	A	D	P	-	-	-	-	-	-	-	AvLib-3	progesterone	
sbAvd-4 [38]	-	R	M	N	H	-	P	Y	L	S	-	-	-	-	-	-	-	AvLib-3	progesterone	
sbAvd-5 [38]	-	R	M	N	H	-	V	P	H	P	-	-	-	-	-	-	-	AvLib-3	progesterone	

(Continued)

Table 2. (Continued)

sbAvd-6 [38]	L1,2 loop					L3,4 loop					L5,6 loop				AvLib-3	progesterone		
	-	R	M	N	H	-	V	S	S	N	-	-	-	-				-
	-	R	M	N	H	-	V	S	S	N	-	-	-	-	-	-		

^aCalculated from transformation activity

^bLibrary design based on the enriched sequences with affinity towards progesterone and testosterone [38], sbAvds

^cLibrary design based on the enriched sequences with affinity towards hydrocortisone and cholic acid [38], hbAvds and cabAvds

<https://doi.org/10.1371/journal.pone.0212339.t002>

importance of a histidine residue at position 16 for high-affinity progesterone binding and reduced biotin-binding affinity, in agreement with our sbAvd-2 (I117Y)-progesterone complex structure (see above). The differences between the previously characterized sbAvds and the new progesterone-binding antidins (sbAvd-7-9) are found at positions 33, 35-38 and 77. Based on our new X-ray structure of sbAvd-2 (I117Y), and amino acid sequence comparisons between sbAvd-2 and sbAvd-7 (Table 2), it seems likely that the RMNH-containing antidins benefit from a small aliphatic side chain, either of alanine or valine, at position 35 (sbAvd-2, 111 nM; sbAvd-5, 108 nM; sbAvd-6, 117 nM; sbAvd-7, 5 nM; Fig 5) and of an aliphatic residue, such as valine or leucine (sbAvd-2; sbAvd-4, 135 nM; sbAvd-9, 13 nM; sbAvd-7), or a residue with a small side chain, such as serine (sbAvd-6; sbAvd-8, 117 nM) at position 37. The residues at position 36 and 38 are not likely to directly affect progesterone binding. Moreover, an alanine residue at position 77 (only in sbAvd-7-9) may have a role in stabilizing the D-ring of progesterone and partially explain the higher affinity of the sbAvd-7-9 antidins for progesterone in comparison to other antidins. Furthermore, a phenylalanine residue (only in sbAvd-8 and sbAvd-10 out of the RMNH-containing antidins) instead of a tyrosine residue at position 33 may reduce the biotin-binding affinity [46], since a tyrosine residue at this position is highly conserved within all known Avds from different species. However, the effect of this




Fig 5. Suggested amino acid replacements in the ligand-binding site of the sbAvd-2 (I117Y)-progesterone complex structure (green carbon atoms; subunit I) [PDB:5LUR] likely to improve the progesterone-binding affinity of the sbAvd-2 (I117Y)-progesterone complex structure. (A) Ala35 and Val37 around the progesterone ligand (sticks) in the sbAvd-2 (I117Y)-progesterone complex structure being respectively replaced by (B) Val35 and Leu37 (sticks; grey carbon atoms). Nitrogen atoms are colored blue and oxygen atoms red.

<https://doi.org/10.1371/journal.pone.0212339.g005>

position-tyrosine versus phenylalanine-on progesterone-binding affinity is not trivial to predict, and our docking analyses were unable answer this question (see below).

Physico-chemical properties of sbAvd-7

The progesterone-binding properties of antidins were studied with a fluorometric assay, where quenching of the intrinsic fluorescence of the protein was measured as a function of the ligand concentration; a dissociation constant (K_d) of 5 nM was determined for the progesterone-sbAvd-7 complex (Fig 6A).

The oligomerization state of sbAvd-7 was inspected with a combination of size exclusion chromatography (SEC) and UV-VIS/right angle light scattering (RALS). Based on SEC analysis, sbAvd-7 was found to be a tetrameric protein similarly to the wild-type chicken Avd. On SEC-UV-VIS/RALS analysis, sbAvd-7 was mainly tetrameric but also larger oligomeric forms were detected (Fig 6B); higher-order oligomeric forms are typically observed for tetrameric Avds in SEC (see for example [47]).

The T_m value of 85.84°C was measured for sbAvd-7 in the absence of ligand (Fig 6C) using differential scanning calorimetry (DSC). Progesterone clearly increased ($\Delta T_m = 10.23^\circ\text{C}$) the thermal stability of sbAvd-7 (Fig 6C), while biotin did not have an effect ($\Delta T_m = 0.27^\circ\text{C}$) on thermal stability (Fig 6C).

Docking analysis of antidins

In order to better understand the atomic interactions that discriminate between stronger and weaker ligand-binding antidins, we conducted molecular docking analysis. We focused on the antidins sbAvd-7–9, which we found to be the highest affinity progesterone binders based on a fluorometry-based assay (see above).

Four out of eleven (sbAvd-7), six out of eight (sbAvd-8) and seven out of sixteen (sbAvd-9) progesterone poses (Fig 7, S1 Table) were found to be docked in a similar orientation, and as deep in the binding pocket, as the ligand was observed in the crystal structure of the sbAvd-2 (I117Y)-progesterone complex [PDB:5LUR]. However, despite extensive visual analysis of the ligand poses, we could not fully explain the difference in the binding affinities of sbAvd-2 (I117Y), sbAvd-7, sbAvd-8 and sbAvd-9 at the atomic level. The putative hydrophobic/van der Waals interactions, even for the docked progesterone ligands closely resembling the orientation of the progesterone ligand in the crystal structure of sbAvd-2 (I117Y), were not trivial to predict; the interaction networks varied among the different progesterone poses on each of the antidins sbAvd-7–9 despite the unique set of mutations in the L3,4 loop region, and at positions 33 and 77. For reference, we also docked the ligand from the crystal structure of the sbAvd-2 (I117Y)-progesterone complex [PDB:5LUR] back into the ligand-binding site and, even in this case, the docking produced varying poses dissimilar to the ligand observed in the crystal structure, indicating the challenge of docking progesterone into Avd-like binding pockets. Interestingly, Panek and coworkers [48] recently reported that progesterone docked into human mineralocorticoid receptor and bacterial monooxygenase in orientation ('D-ring first') different from that observed in the crystal structures of these proteins ('A-ring first').

In addition to progesterone, biotin was also docked to the sbAvd-7–9 antidins. As expected based on the analysis of the sbAvd-2 (I117Y) crystal structures ([PDB:5LUR] and [PDB:4U46] [38]), His16 hinders the biotin binding to these antidins, and we predict it to do so in all antidins selected from the AvLib-4 library having the RMNH-sequence at their L1,2 loop. Moreover, the mutations in the L3,4 loop are likely to further reduce the biotin-binding affinity of sbAvd-7–9, especially in the case of sbAvd-9, in which the bulky tyrosine side chain at position 35 (threonine in chicken Avd) extends into the ligand-binding site.




Fig 6. Biophysical characterization of sbAvd-7 for progesterone binding properties, oligomeric state and thermal stability. Binding affinity ($K_d = 4.9$ nM) was determined (A) measuring intrinsic fluorescence as a function of progesterone concentration. (B) LC-SLS analysis revealed a molecular weight of 65 kDa (Retention volume (RV) 1.647

ml) for sbAvd-7, which corresponds well to the molecular weight of the tetrameric protein calculated from the sequence (MW = 62.6 kDa). Retention volumes of the molecular weight standards: bovine serum albumin (66.7 kDa) 1.547 ml; carbonic anhydrase (29 kDa) 1.792 ml; alcohol dehydrogenase (150 kDa) 1.432 ml and beta amylase (200 kDa) 1.365 ml. (C) Differential scanning calorimetry. Progesterone increased the thermal stability of sbAvd-7, indicating tight interaction between sbAvd-7 and progesterone ($\Delta T_m = 10.23^\circ\text{C}$). In contrast, biotin showed no stabilizing effect ($\Delta T_m = 0.27^\circ\text{C}$).

<https://doi.org/10.1371/journal.pone.0212339.g006>

Detection of progesterone from serum samples

The ability of antidins to detect progesterone was studied using a microplate-based assay (Fig 8A–8F). The effect of the antidin concentration for progesterone and biotin binding was studied using microplates coated with BSA-conjugated progesterone or biotin, and nonspecific binding using BSA-coated microplates. In order to study the residual biotin-binding affinity, free biotin was added to the samples to a final concentration of 10 μM (Fig 8A–8F). The binding of different concentrations of the antidins were measured using antibodies (primary antibody + HRP-conjugated secondary antibody). Based on this assay, the sbAvd-2 and sbAvd-7 antidins were found to be the best progesterone-binders and were thus selected for serum progesterone measurements. As shown in Fig 8G–8I, sbAvd-2 and sbAvd-7 can detect progesterone in phosphate buffer and in progesterone-spiked serum samples over a concentration range of 31.3–500 ng/ml.

Discussion

Avd and streptavidin are widely applied in biotechnological applications because they enable the attachment of biotinylated molecules on a wide array of materials. The structure of the ligand-binding site of (strept)avidin has characteristics optimal for the recognition of small ligands: the binding site is deep and narrow in structure, and the loops at the entrance of the binding-site isolate the bound ligand from the surrounding environment. The aim of this study was to utilize and engineer the biotin-binding site of Avd to develop artificial Avd-based receptors, antidins, for small molecules other than biotin, and in particular for steroids. Furthermore, we aimed to significantly improve the affinity of the previously developed antidins towards progesterone. For this purpose, a synthetic DNA library with tailored randomization was created using TRIM technology. The DNA library was subcloned into phage display vector using Gateway technology and resulted adequate sequence coverage as compared to theoretical library size.

Rational engineering of novel, artificial receptor-ligand pairs is highly dependent on detailed, atomic resolution information about protein-ligand interactions. Here, we solved the structure of the sbAvd-2 (I117Y) antidin [PDB:5LUR] co-crystallized with progesterone and carried out physicochemical analyses in order to help further improve the binding affinity of progesterone to sbAvd-type antidins (Fig 9). The solved X-ray structure pinpoints the importance of Met14 and His16 in the L1,2 loop for high-affinity progesterone binding and low-affinity biotin-binding, and the open conformation of the L3,4 loop hints for optimization of the amino acids of this loop for even higher affinity for progesterone. SbAvd-7, the highest affinity (5 nM) progesterone binder, has an alanine residue at position 35 and a leucine residue at position 37 suggesting that hydrophobic residues are needed at these positions for higher levels of progesterone affinity. Our docking analyses, even though not trivial, are also in agreement with the predictions based on the crystal structure of sbAvd-2 (I117), *i.e.* supporting the idea that the residues at position 35 and 37 of the L3,4 loop in particular, as well as at position 14 and 16 of the L1,2 loop, are critical for ligand specificity and affinity. However, it remains to be seen whether the L3,4 loop of sbAvd-7 containing residues Ala35 and Leu37 is in the open




Fig 7. Principal component analysis (PCA) of RMSD values between all pairs of poses from the sbvd-7 (A), sbAvd-8 (B) and sbAvd-9–progesterone (C) docking experiment. i) The percentage of the total variance displayed on each PCA axis–P (red), Q (blue) and R (green)–is listed in S1 Table. The poses that were docked in a similar orientation as the progesterone ligand seen in the sbAvd-2 (I117Y)–progesterone crystal structure–four for sbAvd-7, six for sbAvd-8 and seven for sbAvd-9–are drawn as orange spheres and other poses as yellow spheres. ii) Comparison of the conformation and relative orientation of the progesterone poses from the docking experiment to the progesterone ligand of the crystal structure (thick sticks, blue carbon atoms). His16 of the crystal structure is also shown. The poses, which are in a similar conformation and orientation as the progesterone ligand in the crystal structure, are drawn as thick sticks (orange carbon atoms) and other poses as thin sticks (yellow carbon atoms). Nitrogen atoms are colored blue and oxygen atoms red.

<https://doi.org/10.1371/journal.pone.0212339.g007>




Fig 8. Determination of progesterone concentration using antindins. For the measurements, the antigen EIA measurement configuration (A) was used. The concentration dependency of the binding was then determined and, based on the results (B–F), antindins sbAvd-7 and sbAvd-2 were selected for the actual progesterone detection range measurements (G–I). The BSA conjugate of progesterone (P4) was: BSA-CMO-P4 (Sari Viitala, University of Eastern Finland).

<https://doi.org/10.1371/journal.pone.0212339.g008>




Fig 9. Summary of mutations introduced to the antitdins sbAvd-1–10 and K_d values for their progesterone binding. The mutated regions/sites are indicated by different colours in the X-ray structure of wt avidin [PDB 2AVI; [19]]; only a monomer is shown for simplicity. The K_d values for progesterone binding were determined using intrinsic fluorescence quenching method.

<https://doi.org/10.1371/journal.pone.0212339.g009>

or closed conformation, or if it is possible to further optimize the residues at position 35 and 37 for tighter progesterone binding. Optimization of residues of the β₆-strand (e.g. at position 77) or from the L5,6 loop (e.g. at position 73 and 75) may also improve the progesterone binding of the sbAvids; for example, mutating Ala77 of sbAvd-7–9 to a valine residue (threonine in sbAvd-2 (I117Y)) or mutating one of the serine residues at position 73 and 75 to a small hydrophobic residue while leaving the other serine for H-bonding with the 3-keto group of progesterone. Mutational analysis of residues especially at positions 14, 16, 35, 37, 73, 75 and 77, and crystallization trials of the sbAvd-7–9-progesterone complexes, would help address these questions.

Our physicochemical analysis of sbAvd-7 (Fig 6)–the tightest progesterone binding antidin produced to date–showed that the engineered avidin is tetrameric similarly to the wild-type protein. Binding of progesterone stabilized sbAvd-7, in agreement with the measured K_d of 5

nM. In contrast to wt Avd, which is strongly stabilized by biotin [39], biotin had a negligible effect on the thermal stability of sbAvd-7, which reflects a significant loss in biotin-binding affinity. Altogether, our findings suggest that avidin tolerates genetic engineering and can be manipulated in terms of ligand-binding specificity, properties that should enable the future development of binders for various small molecules.

We demonstrated that sbAvd-2 and sbAvd-7 can detect progesterone from serum samples down to a concentration of ~30 ng/ml and hence has potential to be used in diagnostics. However, to test *e.g.* breeding times in dog, higher sensitivity and a wider detection range is needed—the progesterone levels in domestic female dog serum ranges between 0.1–60.0 ng/ml, and the most important measurement range is between 1.0–10.0 ng/ml [49].

The vast amount of reagents already available for developing the (strept)avidin-biotin-system, including antibodies, chromatography resins etc. and constant need for improved performance should help drive development of novel Avd-based technologies, including the antidin-steroid protein-ligand pair as a molecular tool. In comparison to the classical (strept)avidin-biotin-system, the novel antidins described here are not affected *e.g.* by endogenous biotin (Fig 8) and, in comparison to antibodies, the high stability of antidins is a clear advantage and may enable the use of antidins in applications where antibodies cannot be used because of stability issues. Furthermore, the expression of antidins in *E. coli* is cost-efficient and straightforward, and therefore one may envision applications for antidins in methods such as chemical synthesis and sample pre-processing.

Materials and methods

Homology modeling

Two different homology models were built for each of the sbAvd-7–9. Firstly, models to study progesterone binding were built using the sbAvd-2 (I117Y)-progesterone complex structure [PDB:5LUR] as a template. The L3,4 loop of this crystal structure is in the open conformation and the residues Val37-Asn42 (subunit I and III) or Val37-Glu43 (subunit II and IV) were missing from the structure and therefore built using the Crosslink proteins panel from the Biologics suite (Maestro 11.3, release 2017–3, Schrödinger, LLC, New York, NY, 2017). The conformation of the L3,4 loops were predicted by searching through the curated structures in the PDB database [50,51] and energy calculations were made using PRIME (Maestro 11.3). Secondly, models to study biotin binding were done using two templates: chicken Avd-biotin complex structure [PDB: 1AVD] [52] with the L3,4 loop in the closed conformation was used as the template structure for all residues except for residues 13–16 of the L1,2 loop for which the sbAvd-2 (I117Y)-progesterone complex structure [PDB:5LUR] was used as the template. Structure-based sequence alignment was made using the program Malign [53] in Bodil [54]. The homology models were created using Modeller 9.14 [55]. Ten tetrameric models were created for each antidin and the models were ranked using the Molecular PDF (molpdf) score and Discreet Optimized Protein Energy (DOPE) score automatically produced by the program. MolProbity [56] was used for checking the stereochemical and geometrical parameters of the final models. More than 96% of the residues of all the models created were in the favoured regions in Ramachandran plots [57]. Final model selection for docking was done based on visual analysis in PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC) and the Ramachandran plots [57].

Molecular docking

Biotin (Pubchem Compound ID: 171548) and progesterone (Pubchem Compound ID: 5994) were retrieved from the NCBI PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) and

were imported into the Maestro 11.3 (Release 2017–3: Schrödinger, LLC, New York, NY, 2017) for minimization using the OPLS_2005 force field in the LigPrep wizard. Possible ionization states were generated at the target pH of 7.0 ± 2.0 using Epik. Counter ions and/or water molecules were removed from the ligand structure and possible tautomers were generated. Geometrical irregularities in the ligands were corrected using the option ‘Retain specified chiralities’.

The Protein Preparation wizard in Maestro 11.3 was used to prepare the progesterone-removed crystal structure of sbAvd-2 (I117Y) [PDB:5LUR] with modeled L3,4 loop (only for progesterone docking) and the selected sbAvd-7–9 models (see above) for progesterone and biotin docking; All protein structures were optimized and minimized using the force field OPLS_2005. Water molecules beyond 5 Å from any amino acid residues were deleted from the heteroatom groups and H-bond assignments were done at the default pH of 7.0 using PROPKA. The amino acid residues at the ligand-binding site equivalent to 16, 39 and 73 of chicken Avd [PDB: 1AVD] were chosen as the centroids of the receptor (sbAvd-2 (I117Y), sbAvd-7–9) for ligand binding with automatic box size determination by the Induced Fit Docking (IFD) wizard [58–60], which utilizes both GLIDE and PRIME programs. The standard protocol was applied and ring conformations were sampled in an energy window of 2.5 kcal/mol by selecting the ‘Sample ring conformation’ option, which samples the rotatable bonds, while leaving the backbone fixed. Amide bonds were allowed to be in cis or trans conformation. In the GLIDE docking tab, the receptor and ligand van der Waals scaling were both kept at the default value of 0.5 to permit enough flexibility for the amino acid side chains and the ligand to dock in the best possible poses. A maximum of 20 poses were allowed per ligand. Amino acid residues having atoms within 5.0 Å of the ligand poses along with their side chains were refined and optimized using the PRIME refinement option. In the redocking option of GLIDE, the extra precision (XP) option was selected and redocking of ligands in a structure was allowed within 30 kcal/mol of the best docked conformation, for a maximum of 20 structures. The results were categorized based on parameters such as the docking score, GLIDE Gscore, PRIME energy and IFD score.

Principal component analysis

Principal component analysis (PCA) was used to display the relationships among the docked poses of two ligands—biotin and progesterone—within the binding site of the antidiins. For each ligand, the root mean-squared distance was computed between all pairs of poses over all ligand atoms using a C program fixrmsd (Johnson, MS; unpublished). For each ligand, the square matrix of distances calculated among the poses was input to the program PCA (Johnson, MS; unpublished) and coordinates representing each pose in three dimensions were output as a PDB formatted files for visualization using the program Bodil [54].

Crystallization and data collection

The sbAvd-2 (I117Y) mutant (1.8 mg/ml; 20 mM sodium phosphate, 1 M sodium chloride, 20 mM imidazole, pH 7.4) was co-crystallized with 50 mM progesterone in 10:1 (v/v) ratio using the vapour diffusion method. Sitting drops (150 nl of the protein-ligand solution + 75 nl of well solution) were prepared with the mosquito liquid handling robot (TTP Labtech). The well solution (0.18 M sodium chloride, 0.09 M sodium cacodylate (pH 6.5) and 1.8 M ammonium sulfate) used was derived from the commercial JCSG-plus crystallization screen (NeXtal Tubes Suites, Qiagen, USA). The crystal used for data collection appeared within a few weeks of incubation on 96-well triple sitting drop iQ plates (TTP Labtech) at 21°C in a temperature controlled crystallization incubator (RUMED model 3201). The X-ray diffraction properties of the

crystals were initially analysed using the PX Scanner (Agilent Technologies). For data collection, 1 μ L of cryoprotectant (12.5% di-ethylene glycol, 12.5% MPD, 37.5% 1,2-propanediol, 12.5% DMSO; CryoProtX, Molecular Dimensions) was added to the crystallization drop just prior to freezing in liquid nitrogen. Data were collected at ESRF beam line ID30A-3, Grenoble (Table 1). Data were processed using XDS [40].

Structure determination and refinement

Initial phase estimates for the structure factors were obtained using the molecular replacement program Phaser [61] within the CCP4i GUI [62–64]. The Matthews coefficient [65] predicted the presence of two molecules per asymmetric unit. For molecular replacement, a monomer of the apo sbAvd-2 (117Y) structure [PDB:4U46] [38] was used as the template. The space group of the structure was confirmed to be $P2_12_12$ after the replacement. The X-ray structure was refined with Refmac5 [41] and edited/rebuilt using Coot [66]. Solvent atoms were added to the structure and the final validation was done using the inbuilt tools of Coot [66] and MolProbity [56]. PyMOL and Bodil [54] were also used to check the final structure, and for creating figures. The coordinate file and structure factors were deposited in the Protein Data Bank [50,51] with the PDB code 5LUR.

Phage display libraries

Two new synthetic Avd gene libraries (AvLib-4–5 libraries, see Table 2) were designed based on the enriched sequences from the previous study [38] and synthesized by Thermo Fisher Scientific Inc. The library AvLib-4 was designed for progesterone panning and is based on the enriched sbAvd-2–6 sequences from AvLib-3 [38], whereas the library AvLib-5 was designed for hydrocortisone panning and is based on the enriched hbAvd-1–2 and cabAvd-1–2 sequences from AvLib-2 [38]. However, we applied limited diversity (in the most extreme case binary sequences of Tyr/Ser) to our library design, inspired by [67,68] in which this technique was successfully used to generate high-affinity and specific protein-protein interactions. The synthetic gene library was constructed using either the chicken Avd gene or its mutant, called sbAvd-1: the genes were diversified using preassembled trinucleotide building blocks within the chemical synthesis process (the TRIM (trinucleotide mutagenesis) technology) enabling the introduction of a restricted set of amino acid residues in the L3,4 loop or in the loops L1,2 and L5,6 (Table 2). Additionally, three amino acid residues essential for biotin-binding [19], were randomized allowing for all of the amino acid residues except cysteine (Table 2). The total number of mutated amino acid residues was eleven or nine. The Shine-Dalgarno (AGAAGGAGATATACAT) and OmpA signal sequences [47] preceded the avidin gene, and the library was flanked with attL sequences in order to enable Gateway (LR) cloning into a compatible phagemid vector [42]. For optimal protein expression, the sequence was codon-optimized for *E. coli*. The synthetic libraries were delivered as an amplified and non-amplified library. The quality of the library had been analyzed by the manufacturer (Thermo Fisher Scientific Inc.) using bulk sequencing.

The phagemid libraries were constructed by LR-cloning the amplified library with the pGWSacBRphagemid vector (1:1 molar ration) in overnight reactions, and subsequently transformed into *E. coli* XL1-Blue cells by electroporation in parallel reactions (essentially as described earlier in [42]). A sample of each reaction was plated enabling transformation efficiency calculations after which the parallel reactions were pooled together and diluted 1:10 with SB medium supplemented with ampicillin (100 μ g/ml), tetracycline (10 μ g/ml), sucrose (10% (w/v)) and glucose (2%). The bacterial culture was allowed to grow in a shaker for 1 h, after which glycerol stocks were prepared. The rest of the culture was used for plasmid extraction, as described in [42]. Briefly, the biopanning was performed using the automated

magnetic bead platform, Precipitor (Abnova, Taipei City, Taiwan) essentially as described in [42] using BSA-conjugated ligands, cortisol-3 BSA conjugate (C037, CalBioReagents Inc.) or progesterone-3-CMO:BSA (prepared by S. Lehtonen and confirmed to contain approximately 3 progesterone molecules per BSA) as target molecules.

Selection of the antidins

Three rounds of selection were performed for the AvLib-4 library specifically designed for progesterone binding. Four different phage production conditions were tried in parallel (1: in the presence of 0.1% glucose to repress the Avd production; 2: 0.1% glucose + biotin (2 g/L) to reduce the toxicity effect of Avd production; 3: 0.1% glucose + 10 mM IPTG to induce protein production; 4: 0.1% glucose + biotin (2 g/L) + 10 mM IPTG), while keeping the elution conditions constant. For biopanning, a magnetic bead platform, Precipitor (Abnova), was used with carboxyl magnetic beads (Abnova) coated according to instructions from the manufacturer. The elution strategy was inspired from the [45], using an excess of free progesterone (20 μ M) in the first round elution and continuing the next two panning rounds by using nonspecific acidic elution [38] instead.

First, the coated beads were blocked with 2.5% milk-PBS (procedure described in [38]), and additionally also with 2% w/v BSA in PBS/T for 1 h (according to [45]) instead of the depletion step with BSA (as described in [38]). The library AvLib-4 *E. coli* XL1-Blue cell culture was grown from glycerol stock essentially as described in [69] in the presence of 100 μ g/ml ampicillin, 10 μ g/ml tetracyclin, 10% sucrose (w/v) and 2% glucose (w/v). The following day, the cell culture was diluted 1/50 and grown in a 10 ml-culture volume in SB+amp+tet+gluc (1%) in four Erlenmeyer bottles (enabling four different culture conditions in parallel) until the $OD_{600} = 0.7-1$. Helper phage coinfection was followed by dilution of the 10 ml-infections to 100 ml-culture volume and grown as described previously. At this point the glucose concentration was lowered to 0.1%. After 30 minutes, for two of the cultures, biotin (2 g/L) was added. After 2 h-incubation, kanamycin (70 μ g/ml) was added, the temperature was reduced and the cultures were grown +28°C O/N. Additionally, for two of the cultures, IPTG (10 mM) was also added. Thus, four different culture conditions were used in parallel. The following day, the phages were collected by PEG-precipitation essentially as described in [69]. The first round elution was performed with 20 μ M progesterone in PBS for 30 min followed by phage production conditions described above and PEG precipitation (essentially as described in [69]), whereas subsequent elution rounds and phage productions were performed as described in [38].

For hydrocortisone selection, two sets consisting of three rounds of panning were performed with the AvLib-5 library using cortisol-3-BSA (CalBioReagents). At first, the used panning conditions were inspired by those described in [70], but here all three different elution conditions (free ligand, acidic and basic elution) were performed in each round and always pooled together. First, both conjugated magnetic beads and phages were blocked with 2% BSA in PBS-Tween (0.05%) overnight +4°C and the phages were subsequently subjected to biotin preincubation for 30 min (RT, 250 rpm) using biotin-BSA (Leppiniemi, J., University of Tampere; 270 ng/well) -coated Nunc MaxiSorp 96-well plate (eBioscience Inc., San Diego, CA, USA). The bead-bound phages were eluted with moderate mixing speed with free hydrocortisone (100 μ M) in PBS-Tween (0.05%) for 30 minutes, after that with 0.1 M trimethylamine base for 6 min and lastly with 0.1 M glycine/HCL pH 2.2 for 8 min. The base and acid elutions were subsequently neutralized with 4.75 μ l of 2 M acetic acid and 14.3 μ l of 0.5 M Tris base, respectively, and the eluates were pooled together and used for infecting 900 μ l exponentially growing *E. coli* XL1-Blue cells. The phages were thus amplified on microplates essentially as described in [71]. The subsequent rounds were performed directly from the phage culture

supernatants (essentially as described in [38]) similarly without biotin-preincubation step. This panning condition yielded the enrichment of antidins hbAvd-4 and hbAvd-5.

Later, hydrocortisone-panning was repeated for the pooled library consisting of both the AvLib-4 and AvLib-5 libraries and, again, three rounds of selection was performed. For elution, however, two different conditions were used: trypsin (1 mg/ml in PBS, 30 min) or free hydrocortisone (100 μ M in PBS, 1 h). This time the phage amplifications after each panning round were carried out in Erlenmeyer flasks followed by PEG precipitation (essentially as described in [69]). Several clones were picked and tested using ELISA for their binding preference for cortisol-3 BSA against BSA and BSA-biotin. Further, the clones with strong ligand binding were selected based on biolayer interferometry (BLI; see supplementary data for the details) and fluorometry. All of the positive clones from the primary selection were sequenced, which resulted in antidins hbAvd-6–9.

Protein production and purification

The most enriched Avd mutants from the hydrocortisone and progesterone pannings were subcloned with the OmpA signal peptide [47] and C-terminal 6xHis-tag into the pET101/D expression vector (Invitrogen) [37]. Proteins were expressed in *E. coli* strain BL21-AI (Invitrogen) or OverExpress C43(DE3) (Lucigen) essentially as previously described [47]. The fresh transformants were cultured in Lysogeny broth (LB) medium with 0.1% (w/v) glucose and ampicillin (100 μ g/ml) at 28°C on a shaker until the culture reached OD₆₀₀ 0.4. Protein expression was then induced by adding 0.2% (w/v) L-arabinose and 1 mM IPTG and the cultivation was continued for an additional 18 hours. Finally, the cells were collected by centrifugation (5000 g, 10 min, 4°C) and frozen.

The proteins were purified using affinity chromatography on a Ni-NTA (QIAGEN) column [37]. The bacterial cell pellets were suspended in binding buffer (20 mM NaH₂PO₄/Na₂HPO₄, 1 M NaCl, 20 mM imidazole, pH 7.4) and lysed by homogenization (EmulsiFlex-C3 homogenizer, Avestin Inc.). After pooling the elution fractions together, the imidazole concentration was reduced back to 20 mM using step-wise dialysis, and subsequently into 50 mM NaH₂PO₄/Na₂HPO₄, 650 mM NaCl, pH 7. The purity and quality of the isolated proteins was analyzed by UV/Vis spectrophotometry, SDS-PAGE, Western blotting with polyclonal anti-avidin antibody (University of Oulu, Finland) and dynamic light scattering—these analyses indicated that the quality of the purified proteins were comparable to that of the bacterially expressed Avd [47], which was used as a reference protein in the assays.

Determination of progesterone concentration from serum samples

Dog serum samples were collected in a study to monitor hormone metabolites in dogs. The study plan CW 14/122 was approved by the ClinVet Committee for Animal Ethics and Welfare (CCAEW). The antigen EIA method was performed essentially as in [38]. At first, Avd- and progesterone-specific polyclonal antibody were tested in parallel, but since the Avd-specific antibody worked better with the antidins, it was selected for further use. Microwell (NUNC Maxisorp) plates were coated with BSA (500 ng/well; bovine serum albumin, A3059 Sigma-Aldrich), progesterone-BSA conjugate (500 ng/well, BSA-CMO-P4, Sari Viitala, University of Eastern Finland) and BSA-biotin (500 ng/well; Jenni Leppiniemi, University of Tampere) in 10 μ M NaHCO₃ (pH 9.5) at +37°C for 2 h. After washing the wells (three times with PBST), the plates were blocked with 0.5% BSA in PBS at +37°C for 30 min. After washing the wells once, the serially diluted antidins (0–7.2 μ g/ml) in 0.5% BSA containing sodium phosphate buffer (50 mM NaH₂PO₄, 650 mM NaCl, pH 7.0 for hbAvd-4, sbAvd-7–10; and 20 mM NaH₂PO₄, 1 M NaCl, pH 7.4 for sbAvd-5 and sbAvd-2) were added in a volume of 100 μ l/well

with and without inhibitor (10 mM D-biotin, 0340 VWR), and incubated at +37°C for 1 h. Followed by three PBST washes, polyclonal anti-avidin IgG (University of Oulu; 1:5000 dilution) was added (100 μ l/well) and the wells were incubated at +37°C for 1 h. After washes, the secondary antibody (HRP-conjugated anti-rabbit IgG 1:10 0000, 611–1322 Rockland) was added 100 μ l/well and incubated at +37°C for 30 min. After the final washing step, 100 μ l/well of 3,3', 5,5' tetramethylbenzidine substrate solution was added and the color was allowed to develop at room temperature for 30 min. The reaction was stopped by adding 50 μ l of 2 M H₂SO₄ and the optical density was determined at 450 nm using a microplate reader (ELx800 BioTek Instruments, Inc, USA).

The sbAvd-2 and sbAvd-7 antidins were used for the progesterone binding assay. Wells were coated with BSA-CMO-P4 and blocked as described above. Progesterone was serially diluted (0–1 μ g/ml) in sample buffer (0.5% BSA, 50 mM NaH₂PO₄, 650 mM NaCl, pH 7.0) and in pre-diluted serum sample (1:25 in sample buffer). SbAvd-2 and sbAvd-7 were diluted in sample buffer for concentrations of 3.6 μ g/ml and 0.9 μ g/ml, respectively, and 100 μ l/well of the progesterone dilutions were added. Wells were incubated at +37°C for 1 h. The binding was detected by the method described above.

Progesterone-binding analysis of selected antidins with fluorometric assay

The binding affinity of the unconjugated small molecules to antidins was determined utilizing the intrinsic fluorescence originating from the aromatic amino acid residues (mainly tryptophan and tyrosine) of Avd and the fluorescence quenching caused by ligand binding. In brief, 100 nM protein samples in 50 mM NaH₂PO₄/Na₂HPO₄, 650 mM NaCl, pH 7 were excited at 280 nm, and emission was collected at 350 nm using QuantaMaster Spectrofluorometer (Photon Technology International, Inc.) with 2 nm slits. The assay was performed in a quartz cuvette with stirring at 25°C. The ligand was added to the protein sample in small aliquots (6–50 000 nM) and the fluorescence intensity was monitored after a short incubation. The dissociation constant (K_d) was determined from the resulting quenching curve using GraphPad Prism (GraphPad Software, Inc.). The data were fitted to a quadratic equation [72] for tight binding interactions, which takes ligand depletion and nonspecific binding into account (described in detail in [38]) (Fig 6).

Differential scanning calorimetry (DSC)

The thermal stability of the antidin sbAvd-7 in the presence and absence of ligands was analyzed using an automated VP-Capillary DSC System (Malvern, Microcal Inc.) essentially as described in [73]. Protein samples in the sodium phosphate buffer (50 mM, pH 7) containing 650 mM NaCl were degassed prior to the measurement. The protein concentration in the cell was 6.4 μ M, and the molar concentration of the ligands (D-biotin (Biochemica, Fluka) and progesterone (Steraloids Inc., USA)) were three times higher (Fig 6).

Size exclusion chromatography with static light scattering (SEC-SLS)

The oligomeric state of the antidin sbAvd-7 was analyzed with size exclusion chromatography (SEC) using a liquid chromatography instrument (CBM-20A, Shimadzu Corporation) equipped with an autosampler (SIL-20A), UV-Vis (SDP-20A), and a fluorescence detector (RF-20Axs). The instrument was integrated with a static light scattering instrument (SLS, Zetasizer μ V light scattering detector (Malvern Instruments Ltd.)) to determine molecular weight of the eluted proteins. The instrument was controlled using Lab Solutions Version 5.51 (Shimadzu Corporation) and OmniSEC 4.7 (Malvern Instruments Ltd.). Samples (~50 μ g in 10–100 μ l) were injected onto a Superdex200 Increase 5/150GL column (GE Healthcare) and

equilibrated with the buffer the protein was dialyzed against (50 mM sodium phosphate, 650 mM NaCl, pH 7) with a flow rate of 0.1 ml/min at 20°C. Molecular weight determination was done by calculating a standard curve based on the elution volume of the molecular weight markers (CA, carbonic anhydrase 29 kDa; BSA, Bovine Serum Albumin 66 kDa; ADH, Alcohol Dehydrogenase 150 kDa; BA, β -Amylase 200 kDa, Sigma-Aldrich), and alternatively, using the light-scattering intensity-based determination protocol involving BSA (monomeric peak) in SLS detector calibration using a Malvern microV detector and the OmniSEC software (Malvern Instruments Ltd.) (Fig 6).

Conclusion

We have used directed evolution and rational mutagenesis to develop new antidins with high affinity towards progesterone. These antidins have high stability and could, in the future, expand the limited pool of useful scaffolds capable of binding small molecules with high specificity and affinity and even challenge traditional antibodies in *e.g.* diagnostic applications. In this regard, we have demonstrated that the highest affinity ($K_d \sim 5$ nM) progesterone-binding antidin, sbAvd-7, can be used to measure progesterone in serum samples. In order to better understand the progesterone-binding mode of the antidins, and as an aid to further optimize the binding and physicochemical properties of antidins, we characterized the crystal structure of the sbAvd-2 (I117Y)–progesterone complex [PDB:5LUR].

Supporting information

S1 Fig. Vector map of the constructed pGWSacBRphagemid and the schematic representing the Gateway LR cloning of the new synthetic DNA libraries into the phagemid vector. (TIF)

S1 Table. Percent of total variance displayed over the first three dimensions in the PCA analysis of the pairwise RMSD values among poses for the docked ligands. (DOCX)

Acknowledgments

We thank the Tampere Protein Technologies core facility for its protein services, and Dr. J.V. Lehtonen at Åbo Akademi University for scientific IT and bioinformatics infrastructure support—both within Biocenter Finland infrastructure networks; and CSC IT Center for Science and the ESFRI ELIXIR for computational infrastructure support. The Structural Bioinformatics Laboratory is part of the Drug Development and Diagnostics Platform of Åbo Akademi University. We acknowledge the European Synchrotron Radiation Facility, Grenoble, for provision of synchrotron radiation facilities, and we would like to thank the local contacts for assistance in using the beamline. We thank Vetcare Finland Oy for the dog serum samples. We also thank Ulla Kiiskinen for technical support.

Author Contributions

Conceptualization: Nitin Agrawal, Soili I. Lehtonen, Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

Data curation: Nitin Agrawal, Soili I. Lehtonen, Vesa P. Hytönen, Tomi T. Airene.

Formal analysis: Nitin Agrawal, Soili I. Lehtonen, Sari Viitala, Juha A. E. Määttä, Vesa P. Hytönen, Tomi T. Airene.

Funding acquisition: Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

Investigation: Nitin Agrawal, Soili I. Lehtonen, Meri Uusi-Mäkelä, Purvi Jain, Sari Viitala, Juha A. E. Määttä, Niklas Kähkönen, Latifeh Azizi, Tiina A. Riihimäki, Tomi T. Airene.

Methodology: Nitin Agrawal, Soili I. Lehtonen, Meri Uusi-Mäkelä, Purvi Jain, Sari Viitala, Juha A. E. Määttä, Niklas Kähkönen, Latifeh Azizi, Tiina A. Riihimäki, Vesa P. Hytönen, Tomi T. Airene.

Project administration: Vesa P. Hytönen, Tomi T. Airene.

Resources: Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

Supervision: Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

Validation: Nitin Agrawal, Soili I. Lehtonen, Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

Visualization: Nitin Agrawal, Soili I. Lehtonen, Vesa P. Hytönen, Tomi T. Airene.

Writing – original draft: Nitin Agrawal, Soili I. Lehtonen, Vesa P. Hytönen, Tomi T. Airene.

Writing – review & editing: Nitin Agrawal, Soili I. Lehtonen, Meri Uusi-Mäkelä, Purvi Jain, Sari Viitala, Juha A. E. Määttä, Niklas Kähkönen, Latifeh Azizi, Tiina A. Riihimäki, Markku S. Kulomaa, Mark S. Johnson, Vesa P. Hytönen, Tomi T. Airene.

References

1. Laitinen OH, Nordlund HR, Hytönen VP, Kulomaa MS. Brave new (strept) avidins in biotechnology. *Trends in biotechnology*. Elsevier; 2007; 25(6):269–77. <https://doi.org/10.1016/j.tibtech.2007.04.001> PMID: 17433846
2. Dundas CM, Demonte D, Park S. Streptavidin-biotin technology: improvements and innovations in chemical and biological applications. *Applied microbiology and biotechnology*. Springer; 2013; 97(21):9343–53. <https://doi.org/10.1007/s00253-013-5232-z> PMID: 24057405
3. Laitinen O, Hytönen V, Nordlund H, Kulomaa M. Genetically engineered avidins and streptavidins. *Cellular and Molecular Life Sciences CMLS*. Springer; 2006; 63(24):2992–3017. <https://doi.org/10.1007/s00018-006-6288-z> PMID: 17086379
4. Hytönen VP, Määttä JAE, Nyholm TKM, Livnah O, Eisenberg-Domovich Y, Hyre D, et al. Design and construction of highly stable, protease-resistant chimeric avidins. *J Biol Chem*. 2005; 280(11):10228–33. <https://doi.org/10.1074/jbc.M414196200> PMID: 15649900
5. Määttä JA, Airene TT, Nordlund HR, Jänis J, Paldanius TA, Vainiotalo P, et al. Rational Modification of Ligand-Binding Preference of Avidin by Circular Permutation and Mutagenesis. *Chembiochem*. Wiley Online Library; 2008; 9(7):1124–35. <https://doi.org/10.1002/cbic.200700671> PMID: 18381715
6. Määttä JA, Eisenberg-Domovich Y, Nordlund HR, Hayouka R, Kulomaa MS, Livnah O, et al. Chimeric avidin shows stability against harsh chemical conditions—biochemical analysis and 3D structure. *Bio-technology and Bioengineering*. Wiley Online Library; 2011; 108(3):481–90. <https://doi.org/10.1002/bit.22962> PMID: 20939005
7. Nordlund HR, Laitinen OH, Hytönen VP, Uotila STH, Porkka E, Kulomaa MS. Construction of a dual chain pseudotetrameric chicken avidin by combining two circularly permuted avidins. *Journal of Biological Chemistry*. ASBMB; 2004; 279(35):36715–9. <https://doi.org/10.1074/jbc.M403496200> PMID: 15131113
8. Nordlund HR, Hytönen VP, Hörhå J, Määttä JAE, White DJ, Halling K, et al. Tetravalent single-chain avidin: from subunits to protein domains via circularly permuted avidins. *Biochem J*. 2005; 392(Pt 3):485–91. <https://doi.org/10.1042/BJ20051038> PMID: 16092919
9. Hytönen VP, Nordlund HR, Hörhå J, Nyholm TKM, Hyre DE, Kulomaa T, et al. Dual-affinity avidin molecules. *Proteins*. 2005; 61(3):597–607. <https://doi.org/10.1002/prot.20604> PMID: 16175628
10. Riihimäki TA, Kukkurainen S, Varjonen S, Hörhå J, Nyholm TK, Kulomaa MS, et al. Construction of chimeric dual-chain avidin by tandem fusion of the related avidins. *PloS one*. Public Library of Science; 2011; 6(5):e20535.

11. Leppiniemi J, Määttä JA, Hammaren H, Soikkeli M, Laitaoja M, Jänis J, et al. Bifunctional avidin with covalently modifiable ligand binding site. *PloS one*. Public Library of Science; 2011; 6(1):e16576. <https://doi.org/10.1371/journal.pone.0016576> PMID: 21305032
12. Elo HA, Kulomaa MS, Tuohimaa PJ. Avidin induction by tissue injury and inflammation in male and female chickens. *Comp Biochem Physiol, B*. 1979; 62(3):237–40. PMID: 318443
13. Siitari H, Alatalo R, Pihlaja M, Hamalainen J, Blount JD, Groothuis TG, et al. Food supplementation reveals constraints and adaptability of egg quality in the magpie *Pica pica*. *Avian biology research*. 2015; 8(4):244–53.
14. Sinkkonen A, Laitinen OH, Leppiniemi J, Vauramo S, Hytönen VP, Setälä H. Positive association between biotin and the abundance of root-feeding nematodes. *Soil Biology and Biochemistry*. 2014; 73:93–5.
15. Banta S, Dooley K, Shur O. Replacing Antibodies: Engineering New Binding Proteins. *Annual Review of Biomedical Engineering*. 2013; 15(1):93–113.
16. Ståhl S, Kronqvist N, Jonsson A, Löfblom J. Affinity proteins and their generation. *Journal of Chemical Technology and Biotechnology*. Wiley Online Library; 2013; 88(1):25–38.
17. Okura H, Mihara H, Takahashi T. Construction of proteins with molecular recognition capabilities using $\alpha\beta\beta$ de novo protein scaffolds. *Protein Engineering Design and Selection*. Oxford Univ Press; 2013; 26(10):705–11.
18. Skerra A. Alternative binding proteins: anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. *FEBS J*. 2008; 275(11):2677–83. <https://doi.org/10.1111/j.1742-4658.2008.06439.x> PMID: 18435758
19. Livnah O, Bayer EA, Wilchek M, Sussman JL. Three-dimensional structures of avidin and the avidin-biotin complex. *Proceedings of the National Academy of Sciences*. National Acad Sciences; 1993; 90(11):5076–80.
20. Eakin RE, Snell EE, Williams RJ. The concentration and assay of avidin, the injury-producing protein in raw egg white. *Journal of Biological Chemistry*. ASBMB; 1941; 140(2):535–43.
21. György P, Rose CS. Cure of Egg-White Injury in Rats by the “Toxic” fraction (AVIDIN) of Egg White given parenterally. *Science*. 1941; 94:261–2. <https://doi.org/10.1126/science.94.2437.261> PMID: 17792887
22. Repo S, Paldanius TA, Hytönen VP, Nyholm TKM, Halling KK, Huuskonen J, et al. Binding properties of HABA-type azo derivatives to avidin and avidin-related protein 4. *Chem Biol*. 2006; 13(10):1029–39. <https://doi.org/10.1016/j.chembiol.2006.08.006> PMID: 17052607
23. Weber P, Pantoliano M, Simons D, Salemme F. Structure-based design of synthetic azobenzene ligands for streptavidin. *Journal of the American Chemical Society*. ACS Publications; 1994; 116(7):2717–24.
24. LeTrong I, Humbert N, Ward TR, Stenkamp RE. Crystallographic analysis of a full-length streptavidin with its C-terminal polypeptide bound in the biotin binding site. *Journal of molecular biology*. Elsevier; 2006; 356(3):738–45. <https://doi.org/10.1016/j.jmb.2005.11.086> PMID: 16384581
25. Leppiniemi J, Grönroos T, Määttä JA, Johnson MS, Kulomaa MS, Hytönen VP, et al. Structure of Brada-vidin-C-Terminal Residues Act as Intrinsic Ligands. *PloS one*. Public Library of Science; 2012; 7(5): e35962. <https://doi.org/10.1371/journal.pone.0035962> PMID: 22574129
26. Avraham O, Meir A, Fish A, Bayer EA, Livnah O. Hoefavidin: A dimeric bacterial avidin with a C-terminal binding tail. *Journal of structural biology*. Elsevier; 2015; 191(2):139–48. <https://doi.org/10.1016/j.jsb.2015.06.020> PMID: 26126731
27. Meyer SC, Gaj T, Ghosh I. Highly selective cyclic peptide ligands for NeutrAvidin and avidin identified by phage display. *Chemical biology & drug design*. Wiley Online Library; 2006; 68(1):3–10.
28. Gaj T, Meyer SC, Ghosh I. The AviD-tag, a NeutrAvidin/avidin specific peptide affinity tag for the immobilization and purification of recombinant proteins. *Protein expression and purification*. Elsevier; 2007; 56(1):54–61. <https://doi.org/10.1016/j.pep.2007.06.010> PMID: 17697784
29. Schmidt TG, Koepke J, Frank R, Skerra A. Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. *Journal of molecular biology*. Elsevier; 1996; 255(5):753–66. <https://doi.org/10.1006/jmbi.1996.0061> PMID: 8636976
30. Voss S, Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. *Protein engineering*. Oxford Univ Press; 1997; 10(8):975–82.
31. Skerra A, Schmidt TG. Applications of a peptide ligand for streptavidin: the Strep-tag. *Biomolecular engineering*. Elsevier; 1999; 16(1):79–86.
32. Skerra A, Schmidt T. Use of the Strep-Tag and streptavidin for detection and purification of recombinant proteins. *Methods in enzymology*. 2000; 326:271. PMID: 11036648

33. Korndörfer IP, Skerra A. Improved affinity of engineered streptavidin for the Strep-tag II peptide is due to a fixed open conformation of the lid-like loop at the binding site. *Protein science*. Wiley Online Library; 2002; 11(4):883–93.
34. Lamla T, Erdmann VA. The Nano-tag, a streptavidin-binding peptide for the purification and detection of recombinant proteins. *Protein expression and purification*. Elsevier; 2004; 33(1):39–47. <https://doi.org/10.1016/j.pep.2003.08.014> PMID: 14680960
35. Perbandt M, Bruns O, Vallazza M, Lamla T, Betzel C, Erdmann V. High resolution structure of streptavidin in complex with a novel high affinity peptide tag mimicking the biotin binding motif. *Proteins: Structure, Function, and Bioinformatics*. Wiley Online Library; 2007; 67(4):1147–53.
36. Keefe AD, Wilson DS, Seelig B, Szostak JW. One-step purification of recombinant proteins using a nanomolar-affinity streptavidin-binding peptide, the SBP-Tag. *Protein expression and purification*. Elsevier; 2001; 23(3):440–6. <https://doi.org/10.1006/prep.2001.1515> PMID: 11722181
37. Riihimäki TA, Hiltunen S, Rangl M, Nordlund HR, Määttä JAE, Ebner A, et al. Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein. *BMC Biotechnol*. 2011; 11:64. <https://doi.org/10.1186/1472-6750-11-64> PMID: 21658230
38. Lehtonen SI, Tullila A, Agrawal N, Kukkurainen S, Kähkönen N, Koskinen M, et al. Artificial Avidin-Based Receptors for a Panel of Small Molecules. *ACS Chem Biol*. 2016; 11(1):211–21. <https://doi.org/10.1021/acscchembio.5b00906> PMID: 26550684
39. Hytönen VP, Nyholm TK, Pentikäinen OT, Vaarno J, Porkka EJ, Nordlund HR, et al. Chicken avidin-related protein 4/5 shows superior thermal stability when compared with avidin while retaining high affinity to biotin. *Journal of Biological Chemistry*. ASBMB; 2004; 279(10):9337–43. <https://doi.org/10.1074/jbc.M310989200> PMID: 14660583
40. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *Journal of applied crystallography*. International Union of Crystallography; 1993; 26(6):795–800.
41. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallographica Section D: Biological Crystallography*. International Union of Crystallography; 2011; 67(4):355–67.
42. Lehtonen S, Taskinen B, Ojala E, Kukkurainen S, Rahikainen R, Riihimäki T, et al. Efficient preparation of shuffled DNA libraries through recombination (Gateway) cloning. *Protein engineering, design & selection: PEDS*. 2015; 28(1):23.
43. Bernard P. Positive selection of recombinant DNA by CcdB. *BioTechniques*. 1996; 21(2):320–3. <https://doi.org/10.2144/96212pf01> PMID: 8862819
44. Traore SM, Zhao B. A novel Gateway-compatible binary vector allows direct selection of recombinant clones in *Agrobacterium tumefaciens*. *Plant Methods*. 2011; 7(1):42. <https://doi.org/10.1186/1746-4811-7-42> PMID: 22145613
45. Gebauer M, Skerra A. Anticalins small engineered binding proteins based on the lipocalin scaffold. *Meth Enzymol*. 2012; 503:157–88. <https://doi.org/10.1016/B978-0-12-396962-0.00007-0> PMID: 22230569
46. Marttila AT, Hytönen VP, Laitinen OH, Bayer EA, Wilchek M, Kulomaa MS. Mutation of the important Tyr-33 residue of chicken avidin: functional and structural consequences. *Biochem J*. 2003; 369(Pt 2):249–54. <https://doi.org/10.1042/BJ20020886> PMID: 12358604
47. Hytönen VP, Laitinen OH, Airene TT, Kidron H, Meltola NJ, Porkka EJ, et al. Efficient production of active chicken avidin using a bacterial signal peptide in *Escherichia coli*. *Biochem J*. 2004; 384(Pt 2):385–90. <https://doi.org/10.1042/BJ20041114> PMID: 15324300
48. Panek A, Świzdor A, Milecka-Tronina N, Panek JJ. Insight into the orientational versatility of steroid substrates—a docking and molecular dynamics study of a steroid receptor and steroid monooxygenase. *J Mol Model*. 2017; 23(3):96. <https://doi.org/10.1007/s00894-017-3278-z> PMID: 28251412
49. Concannon PW. Reproductive cycles of the domestic bitch. *Anim Reprod Sci*. 2011; 124(3–4):200–10. <https://doi.org/10.1016/j.anireprosci.2010.08.028> PMID: 21055888
50. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, et al. The protein data bank. *Nucleic acids research*. Oxford Univ Press; 2000; 28(1):235–42. PMID: 10592235
51. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, et al. The Protein Data Bank. *Acta Crystallogr D Biol Crystallogr*. 2002; 58(Pt 6 No 1):899–907.
52. Pugliese L, Coda A, Malcovati M, Bolognesi M. Three-dimensional structure of the tetragonal crystal form of egg-white avidin in its functional complex with biotin at 2.7 Å resolution. *Journal of molecular biology*. Elsevier; 1993; 231(3):698–710. <https://doi.org/10.1006/jmbi.1993.1321> PMID: 8515446
53. Johnson MS, Overington JP. A structural basis for sequence comparisons: an evaluation of scoring methodologies. *Journal of molecular biology*. Elsevier; 1993; 233(4):716–38. <https://doi.org/10.1006/jmbi.1993.1548> PMID: 8411177

54. Lehtonen JV, Still D-J, Rantanen V-V, Ekholm J, Björklund D, Iftikhar Z, et al. BODIL: a molecular modeling environment for structure-function analysis and drug design. *J Comput Aided Mol Des*. 2004; 18(6):401–19. PMID: [15663001](#)
55. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *Journal of molecular biology*. Elsevier; 1993; 234(3):779–815. <https://doi.org/10.1006/jmbi.1993.1626> PMID: [8254673](#)
56. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res*. 2007; 35(Web Server issue): W375–83. <https://doi.org/10.1093/nar/gkm216> PMID: [17452350](#)
57. Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain configurations. *Journal of molecular biology*. Academic Press; 1963; 7(1):95–9.
58. Farid R, Day T, Friesner RA, Pearlstein RA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. *Bioorganic & medicinal chemistry*. Elsevier; 2006; 14(9):3160–73.
59. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. *Journal of medicinal chemistry*. ACS Publications; 2006; 49(2):534–53. <https://doi.org/10.1021/jm050540c> PMID: [16420040](#)
60. Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. *Chemical biology & drug design*. Wiley Online Library; 2006; 67(1):83–4.
61. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *Journal of applied crystallography*. International Union of Crystallography; 2007; 40(4):658–74.
62. Bailey S. The CCP4 suite: programs for protein crystallography. Daresbury Laboratory; 1993;
63. Potterton E, Briggs P, Turkenburg M, Dodson E. A graphical user interface to the CCP4 program suite. *Acta Crystallographica Section D: Biological Crystallography*. International Union of Crystallography; 2003; 59(7):1131–7.
64. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr*. 2011;67(Pt 4):235–42.
65. Matthews BW. Solvent content of protein crystals. *Journal of molecular biology*. Elsevier; 1968; 33(2):491–7. PMID: [5700707](#)
66. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallographica Section D: Biological Crystallography*. International Union of Crystallography; 2004; 60(12):2126–32.
67. Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. Molecular recognition by a binary code. *J Mol Biol*. 2005; 348(5):1153–62. <https://doi.org/10.1016/j.jmb.2005.03.041> PMID: [15854651](#)
68. Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. *Proc Natl Acad Sci USA*. 2004; 101(34):12467–72. <https://doi.org/10.1073/pnas.0401786101> PMID: [15306681](#)
69. Niederhauser B, Siivonen J, Määttä JA, Jänis J, Kulomaa MS, Hytönen VP. DNA family shuffling within the chicken avidin protein family-A shortcut to more powerful protein tools. *Journal of biotechnology*. Elsevier; 2012; 157(1):38–49. <https://doi.org/10.1016/j.jbiotec.2011.10.014> PMID: [22100264](#)
70. Gebauer M, Schiefner A, Matschiner G, Skerra A. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin. *J Mol Biol*. 2013; 425(4):780–802. <https://doi.org/10.1016/j.jmb.2012.12.004> PMID: [23238252](#)
71. Turunen L, Takkinen K, Söderlund H, Pulli T. Automated panning and screening procedure on microplates for antibody generation from phage display libraries. *J Biomol Screen*. 2009; 14(3):282–93. <https://doi.org/10.1177/1087057108330113> PMID: [19224869](#)
72. Swillens S. Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis. *Molecular Pharmacology*. ASPET; 1995; 47(6):1197–203.
73. Taskinen B, Airene TT, Jänis J, Rahikainen R, Johnson MS, Kulomaa MS, et al. A novel chimeric avidin with increased thermal stability using DNA shuffling. *PLoS ONE*. 2014; 9(3):e92058. <https://doi.org/10.1371/journal.pone.0092058> PMID: [24632863](#)